학술논문
A novel capillary nano-immunoassay for assessing androgen receptor splice variant 7 in plasma. Correlation with CD133 antigen expression in circulating tumor cells. A pilot study in prostate cancer patients.
Document Type
Academic Journal
Author
García JL; Institute of Biomedical Research of Salamanca (IBSAL), Centro de Investigación del Cáncer-IBMCC (USAL-CSIC), Paseo de San Vicente, 58-182, 37007, Salamanca, Spain. jlgarcia@usal.es.; Lozano R; Medical Oncology Service, Hospital Universitario de Salamanca Institute of Biomedical Research of Salamanca (IBSAL), Paseo de San Vicente, 58-182, 37007, Salamanca, Spain.; Misiewicz-Krzeminska I; Institute of Biomedical Research of Salamanca (IBSAL), Centro de Investigación del Cáncer-IBMCC (USAL-CSIC), Paseo de San Vicente, 58-182, 37007, Salamanca, Spain.; Fernández-Mateos J; Medical Oncology Service, Hospital Universitario de Salamanca Institute of Biomedical Research of Salamanca (IBSAL), Paseo de San Vicente, 58-182, 37007, Salamanca, Spain.; Krzeminski P; Institute of Biomedical Research of Salamanca (IBSAL), Centro de Investigación del Cáncer-IBMCC (USAL-CSIC), Paseo de San Vicente, 58-182, 37007, Salamanca, Spain.; Alfonso S; Medical Oncology Service, Hospital Universitario de Salamanca Institute of Biomedical Research of Salamanca (IBSAL), Paseo de San Vicente, 58-182, 37007, Salamanca, Spain.; Marcos RA; Dpto. de Oncología Médica, Complejo Asistencial Nuestra Señora de Sonsoles, Av.Juan Carlos I, s/n, 05071, Ávila, Spain.; García R; Medical Oncology Service, Hospital Universitario de Salamanca Institute of Biomedical Research of Salamanca (IBSAL), Paseo de San Vicente, 58-182, 37007, Salamanca, Spain.; Gómez-Veiga F; Urology Department, Hospital Universitario de Salamanca Grupo de Investigación Traslacional de Urología (GITUR), Institute of Biomedical Research of Salamanca (IBSAL), Paseo de San Vicente, 58-182, 37007, Salamanca, Spain.; Virseda Á; Urology Department, Hospital Universitario de Salamanca Grupo de Investigación Traslacional de Urología (GITUR), Institute of Biomedical Research of Salamanca (IBSAL), Paseo de San Vicente, 58-182, 37007, Salamanca, Spain.; Herrero M; Urology Department, Hospital Universitario de Salamanca Grupo de Investigación Traslacional de Urología (GITUR), Institute of Biomedical Research of Salamanca (IBSAL), Paseo de San Vicente, 58-182, 37007, Salamanca, Spain.; Olmos D; Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), C/Melchor Fernández Almagro, 3, 28029, Madrid, Spain.; Medical Oncology Department, CNIO-IBIMA Genitourinary Cancer Clinical Research Unit, Hospital Universitario Virgen de la Victoria y Regional de Málaga, Campus de Teatinos S/N, 29010, Málaga, Spain.; Cruz-Hernández JJ; Medical Oncology Service, Hospital Universitario de Salamanca Institute of Biomedical Research of Salamanca (IBSAL), Paseo de San Vicente, 58-182, 37007, Salamanca, Spain. jjcruz@usal.es.
Source
Publisher: Country of Publication: Italy NLM ID: 101247119 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1699-3055 (Electronic) Linking ISSN: 1699048X NLM ISO Abbreviation: Clin Transl Oncol Subsets: MEDLINE
Subject
Language
English
Abstract
Purpose: Androgen receptor (AR) splice variant 7 (AR-V7) has been related with both a higher risk of prostate cancer (PC) progression and differential responsiveness to hormonal agents versus chemotherapy. The objective of this study was to investigate the feasibility of a novel capillary nano-immunoassay in assessing AR-V7 in plasma from PC patients.
Methods: Patients with either localized or advanced PC were included in the study. Assessment of AR-V7 in plasma was performed through a capillary nano-immunoassay platform. Correlation with clinical data, stem cell biomarkers (such as CD133+), AR amplification and PTEN status was identified.
Results: The study included 72 PC patients. AR-V7 signal was detected in 21 (29%) patients: 17 (81%) had a Gleason score ≥7, 15 (71%) castration-resistant prostate cancer (CRPC), 18 (86%) metastatic disease and PSA (median) high than AR-V7 negative (p < 0.05). CD133 was expressed in 69 (96%) patients. The median CD133+ expression in circulating tumor cells CTCs was higher among the 21 AR-V7 positive cases versus AR-V7 negative (7 vs. 3). Androgen Receptor and PTEN fluorescence in situ hybridization (FISH) on CD133+ captured cells were performed: 37 cases showed ≥four CD133+ CTCs, of which 81% showed an increased AR copy number. This percentage was similar in both AR-V7-positive and AR-V7-negative patients. A total of 68% of the cases showed deletion of PTEN: 70% were ARV-7 positive vs. 67%, which were AR-V7 negative.
Conclusions: Assessing the presence of AR-V7 in plasma from PC patients is feasible by a novel capillary nano-immunoassay. AR-V7 was observed in 29% of the tumors and is more frequent in aggressive tumors.
Methods: Patients with either localized or advanced PC were included in the study. Assessment of AR-V7 in plasma was performed through a capillary nano-immunoassay platform. Correlation with clinical data, stem cell biomarkers (such as CD133+), AR amplification and PTEN status was identified.
Results: The study included 72 PC patients. AR-V7 signal was detected in 21 (29%) patients: 17 (81%) had a Gleason score ≥7, 15 (71%) castration-resistant prostate cancer (CRPC), 18 (86%) metastatic disease and PSA (median) high than AR-V7 negative (p < 0.05). CD133 was expressed in 69 (96%) patients. The median CD133+ expression in circulating tumor cells CTCs was higher among the 21 AR-V7 positive cases versus AR-V7 negative (7 vs. 3). Androgen Receptor and PTEN fluorescence in situ hybridization (FISH) on CD133+ captured cells were performed: 37 cases showed ≥four CD133+ CTCs, of which 81% showed an increased AR copy number. This percentage was similar in both AR-V7-positive and AR-V7-negative patients. A total of 68% of the cases showed deletion of PTEN: 70% were ARV-7 positive vs. 67%, which were AR-V7 negative.
Conclusions: Assessing the presence of AR-V7 in plasma from PC patients is feasible by a novel capillary nano-immunoassay. AR-V7 was observed in 29% of the tumors and is more frequent in aggressive tumors.